Overview

This trial is active, not recruiting.

Condition diabetic macular edema
Treatment kvd001 injection
Phase phase 1
Sponsor KalVista Pharmaceuticals, Ltd.
Collaborator Juvenile Diabetes Research Foundation
Start date July 2014
End date June 2015
Trial size 17 participants
Trial identifier NCT02193113, KVD001-001

Summary

This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first step to investigate the hypothesis that plasma kallikrein plays an important role in the disease process behind diabetic macular edema in many patients

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
kvd001 injection KVD001
A novel plasma kallikrein inhibitor
(Experimental)
Single 100uL intravitreal injection KVD001 injection Dose 2
kvd001 injection KVD001
A novel plasma kallikrein inhibitor
(Experimental)
Single 100uL intravitreal injection of KVD001 injection Dose 3
kvd001 injection KVD001
A novel plasma kallikrein inhibitor

Primary Outcomes

Measure
Number of participants with Adverse Events as a measure of safety and tolerability
time frame: 56 days

Secondary Outcomes

Measure
Measurement of KVD001 plasma levels over time following intravitreal injection (with calculation of Tmax, Cmax, AUC and t1/2)
time frame: 28 days
Best Corrected Visual Acuity as measured by ETDRS EVA
time frame: 56 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Male or female adult subjects 18 years of age and older 2. Confirmed diagnosis of Type I or Type II diabetes mellitus 3. Best corrected visual acuity, using Early Treatment Diabetic Retinopathy Study (ETDRS) electronic visual acuity (EVA) testing, of between 20/40 and 20/400 (Snellen equivalent) in the study eye 4. Fellow eye acuity 20/80 or better measured as above with no expectation of requirement for anti-VEGF treatment in fellow eye within 2 months of study drug administration 5. Presence of central involved DME in the study eye defined as Optical Coherence Tomography (OCT) Central Subfold Thickness (CST) ≥305 µm in women and ≥320 µm in men in the study eye 6. Subjects who fulfil one of the following criteria: 1. Subjects who have not previously received an anti-VEGF treatment and who, in the view of the Investigator, can have initiation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration 2. Subjects who are receiving regular anti-VEGF intravitreal injections who: - Have received at least 3 intravitreal injections of an anti-VEGF treatment within the last 5 months (study drug administration will be at least 6 weeks after the most recent intravitreal administration of anti-VEGF) and - In the view of the Investigator, can have continuation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration 3. Subjects who have received anti-VEGF in the past (>3 months prior to study inclusion) but are not actively receiving treatment and who in the view of the Investigator, can have resumption of anti-VEGF or alternative treatment in the study eye deferred for at least 2 months following anticipated study drug administration 7. Subjects, who in the view of the Investigator, are not expected to require panretinal laser photocoagulation or intravitreal steroids or intraocular surgery in the study eye for at least 2 months following anticipated study drug administration 8. No prior treatment with panretinal photocoagulation or intravitreal steroid in the study eye within the previous 3 months 9. No prior treatment with systemic corticosteroids or systemic anti-VEGF therapy within the previous 3 months 10. Study participant voluntarily agrees to participate in this study and signs the Institutional Review Board (IRB) approved informed consent prior to performing any procedure Exclusion Criteria: 1. Females who are pregnant or lactating, or expecting to become pregnant during the course of the study 2. Poorly controlled diabetes mellitus 3. Uncontrolled hypertension 4. Significant co-existing disease 5. Participation in an investigational intervention clinical study within 2 months prior to study inclusion 6. History of alcohol and/or drug abuse in the last 2 years 7. Men not willing to use appropriate birth control methods 8. Media clarity or pupillary dilation inadequate to obtain reasonable quality OCT and/or fundus image 9. Subjects employed by the Sponsor or in any relationship of dependence with the Sponsor and/or Investigator

Additional Information

Official title An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Principal investigator Jennifer Sun, MD, MPH
Description The plasma kallikrein-kinin system has long been recognized as a key player in inflammatory processes, capillary leakage and angiogenesis in various organs. Recent work suggests that plasma kallikrein is central to the pathogenesis of Diabetic Macular Edema (DME) and that activation of the enzyme contributes to the excessive retinal vascular permeability leading to DME. Among different persons with DME, plasma kallikrein contributes both independently in some, and in association with Vascular Endothelial Growth Factor (VEGF) in others. However, the effect of plasma kallikrein appears to be independent of VEGF. Thus, growing scientific evidence points to plasma kallikrein inhibitors as an exciting potential new therapeutic opportunity directed at a novel VEGF-independent pathway that may reduce retinal vascular permeability and treat DME, in patients whose disease process is, at least in part, driven by the plasma kallikrein pathway. This is an open label, single ascending dose study to investigate the safety, tolerability and pharmacodynamics of a novel plasma kallikrein inhibitor administered by intravitreal (IVT) injection in subjects with central involved diabetic macular edema and reduced vision.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by KalVista Pharmaceuticals, Ltd..